This finding has led to different clinical phase 1 trials to evaluate the efficacy and safety of the NKG2A blockade in patients with CLL disease (NCT02557516) or in a post-allogeneic SCT setting (NCT02921685). The gene discussed is KLRC1; the disease is B-cell chronic lymphocytic leukemia.